Amyloid-Journal of Protein Folding Disorders

Papers
(The median citation count of Amyloid-Journal of Protein Folding Disorders is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee282
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee150
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial131
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis71
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis60
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines56
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group35
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres29
Association between spinal stenosis and wild-type ATTR amyloidosis27
Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies25
New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden20
Amyloidosis from the patient perspective: the French daily impact of amyloidosis study19
Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience18
A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)15
Cerebral amyloid angiopathy in a 51-year-old patient with embolization by dura mater extract and surgery for nasopharyngeal angiofibroma at age 1715
Clinicopathological features of clinically undiagnosed sporadic transthyretin cardiac amyloidosis: a forensic autopsy-based series14
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure13
A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis13
Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)13
Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease12
Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy12
Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience12
Metabolomics analysis for diagnosis and biomarker discovery of transthyretin amyloidosis12
Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type11
Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial10
The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients10
The role of serial 99mTc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis9
Steep increase in the number of transthyretin-positive cardiac biopsy cases in Japan: evidence obtained by the nation-wide pathology consultation for the typing diagnosis of amyloidosis9
Lysozyme amyloidosis—a report on a large German cohort and the characterisation of a novel amyloidogenic lysozyme gene variant9
Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays9
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study9
Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study9
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study8
Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain8
The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre8
CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis7
Early events in light chain aggregation at physiological pH reveal new insights on assembly, stability, and aggregate dissociation7
Quantitative sensory testing: a good tool to identify subclinical neuropathy in ATTRV30M amyloidosis patients?7
Full-length TDP-43 and its C-terminal domain form filaments in vitro having non-amyloid properties7
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis7
Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation7
Utilization and tolerance of beta-blockers among patients with AL amyloidosis6
Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis6
Reduction in 99m Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy6
Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis6
Identification of AL proteins from 10 λ-AL amyloidosis patients by mass spectrometry extracted from abdominal fat and heart tissue6
Beyond Val30Met transthyretin (TTR): variants associated with age-at-onset in hereditary ATTRv amyloidosis6
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange6
Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis6
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay6
EGF-containing fibulin-like extracellular matrix protein 1 amyloid incidentally found in surgically resected specimens of Colon cancer: a case report emphasising on an unrecognised type5
Binding of serum-derived amyloid-associated proteins to amyloid fibrils5
Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution5
A multicentric study of the disease risks and first manifestations in hereditary transthyretin amyloidosis (ATTRv): insights for an earlier diagnosis5
Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis5
Complement 9 in amyloid deposits5
Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis5
Quantitative proteome profiling provides evidence of an activation of the complement cascade in ATTR amyloidosis5
Collagen inhibits phagocytosis of amyloid in vitro and in vivo and may act as a ‘don’t eat me’ signal5
Heterogeneous worldwide access and pricing of Tafamidis5
Epidemiology of hereditary transthyretin amyloidosis in the northernmost region of Sweden: a retrospective cohort study5
Cardiac manifestations in Finnish gelsolin amyloidosis patients5
Enhanced detection of ATTR amyloid using a nanofibril-based assay4
Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis4
In search of the most effective therapy for light chain amyloidosis4
Iatrogenic cerebral amyloid angiopathy rather than sporadic CAA in younger adults with lobar intracerebral haemorrhage4
Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response4
AA amyloidosis in inflammatory active malignant paraganglioma4
Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy4
Apolipoprotein AI amyloid deposits in the ligamentum flavum in patients with lumbar spinal canal stenosis4
Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis4
Characterization of population genetic structure of hereditary transthyretin amyloidosis in Bulgaria4
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis3
The impact of Post-Transplant doxycycline in AL amyloidosis – updated results after Long-Term follow up3
Progressive vitreous deposits during treatment with inotersen for hereditary ATTR amyloidosis3
Apolipoprotein A-IV amyloidosis in a cotton-top tamarin (Saguinus oedipus)3
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis3
Alterations in multi-layer strain in AL amyloidosis3
A rat model expressing a human amyloidogenic kappa light chain3
Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival3
Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis3
Mass spectrometry-based proteomic analysis of parathyroid adenomas reveals PTH as a new human hormone-derived amyloid fibril protein3
The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis3
The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic transthyretin expression2
Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice2
Absence of an increased wall thickness does not rule out cardiac amyloidosis2
Subtyping of cardiac amyloidosis by mass spectrometry-based proteomics of endomyocardial biopsies2
Novel histopathological deposition patterns of EGF-containing fibulin-like extracellular matrix protein 1 amyloidosis: an autopsy case exhibiting a possible association between AEFEMP1 amyloidosis and2
Survey of amyloidosis cases among different free-living wild and zoo animals2
A second case of liraglutide-type localised amyloidosis2
Management of AL amyloidosis in 2021+2
Functional and morphometric assessment of small-fibre damage in late-onset hereditary transthyretin amyloidosis with polyneuropathy: the controversial relation between small-fibre-related symptoms and2
Somatostatin-derived amyloidosis: a novel type of amyloidosis associated with well-differentiated somatostatin-producing neuroendocrine tumours2
Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis2
Factors affecting the accuracy of amyloidosis identification and referral to a specialty centre2
A case of asymmetric insulin-derived localised amyloid deposition associated with long-acting insulin analog administration2
Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy2
Biochemical and biophysical properties of an unreported T96R mutation causing transthyretin cardiac amyloidosis2
How well does liver span as part of the consensus criteria for liver involvement in AL amyloidosis perform?2
0.029968976974487